A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Clinical trial NCT04879329 · RECRUITING
Trial details
- NCT number
- NCT04879329
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-03
- Primary completion
- 2026-12-11
- Enrollment
- 372
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.